JP7640065B2 - 医薬組成物を調製する方法及び医薬組成物 - Google Patents

医薬組成物を調製する方法及び医薬組成物 Download PDF

Info

Publication number
JP7640065B2
JP7640065B2 JP2020153558A JP2020153558A JP7640065B2 JP 7640065 B2 JP7640065 B2 JP 7640065B2 JP 2020153558 A JP2020153558 A JP 2020153558A JP 2020153558 A JP2020153558 A JP 2020153558A JP 7640065 B2 JP7640065 B2 JP 7640065B2
Authority
JP
Japan
Prior art keywords
cellulose
pharmaceutical composition
pharmaceutical
water
cnc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020153558A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021046392A (ja
JP2021046392A5 (https=
Inventor
マルクス ヌオッポネン
ホアン シアン
ハイチウ ソン
ユーロン ワン
ヤンシン リウ
Original Assignee
ユー ピー エム キュンメネ コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユー ピー エム キュンメネ コーポレーション filed Critical ユー ピー エム キュンメネ コーポレーション
Publication of JP2021046392A publication Critical patent/JP2021046392A/ja
Publication of JP2021046392A5 publication Critical patent/JP2021046392A5/ja
Application granted granted Critical
Publication of JP7640065B2 publication Critical patent/JP7640065B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020153558A 2019-09-13 2020-09-14 医薬組成物を調製する方法及び医薬組成物 Active JP7640065B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19397527 2019-09-13
EP19397527.3A EP3791864A1 (en) 2019-09-13 2019-09-13 Method for preparing pharmaceutical composition and pharmaceutical composition

Publications (3)

Publication Number Publication Date
JP2021046392A JP2021046392A (ja) 2021-03-25
JP2021046392A5 JP2021046392A5 (https=) 2023-08-10
JP7640065B2 true JP7640065B2 (ja) 2025-03-05

Family

ID=67997550

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020153558A Active JP7640065B2 (ja) 2019-09-13 2020-09-14 医薬組成物を調製する方法及び医薬組成物

Country Status (5)

Country Link
US (1) US11723867B2 (https=)
EP (1) EP3791864A1 (https=)
JP (1) JP7640065B2 (https=)
KR (1) KR20210032280A (https=)
CN (1) CN112494430B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3791858A1 (en) 2019-09-13 2021-03-17 UPM-Kymmene Corporation Injectable pharmaceutical formulation
JP2021090882A (ja) * 2021-03-19 2021-06-17 株式会社三洋物産 遊技機
JP2021090883A (ja) * 2021-03-19 2021-06-17 株式会社三洋物産 遊技機
JP2021090879A (ja) * 2021-03-19 2021-06-17 株式会社三洋物産 遊技機
JP2021090881A (ja) * 2021-03-19 2021-06-17 株式会社三洋物産 遊技機
JP2021090884A (ja) * 2021-03-19 2021-06-17 株式会社三洋物産 遊技機
CN116764001B (zh) * 2023-06-29 2025-11-11 上海交通大学医学院附属第九人民医院 多孔碳基双载药纳米缓释材料及其子宫支架与应用
WO2025155702A1 (en) * 2024-01-19 2025-07-24 University Of Maine System Board Of Trustees Cellulose-based hydrogels as vaccine adjuvants
CN119528842B (zh) * 2024-10-25 2025-12-16 上海工程技术大学 一种通过氧化纳米纤维素调控药物晶型的方法及应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014533296A (ja) 2011-11-15 2014-12-11 ユー ピー エム キュンメネ コーポレーションＵｐｍ−Ｋｙｍｍｅｎｅｃｏｒｐｏｒａｔｉｏｎ 生物活性剤の持続性送達のためのドラッグデリバリーシステム
US20150335753A1 (en) 2012-12-19 2015-11-26 Kashiv Pharma, Llc Supersaturated stabilized nanoparticles for poorly soluble drugs
JP2017155195A (ja) 2016-03-04 2017-09-07 第一工業製薬株式会社 パラミロン水性分散液及び細胞増殖促進剤

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4308336B2 (ja) * 1997-03-14 2009-08-05 株式会社日本吸収体技術研究所 ミクロフィブリル状微細繊維構造体およびその製造方法
AU757605B2 (en) 1999-01-28 2003-02-27 Indevus Pharmaceuticals, Inc. Hydrogel compositions useful for the sustained release of macromolecules and methods of making same
FI20095638A0 (fi) 2009-06-09 2009-06-09 Valtion Teknillinen Hydrofobiineja aktiivisten aineiden dispergointiin
FI123988B (fi) 2010-10-27 2014-01-31 Upm Kymmene Corp Soluviljelymateriaali
FI126109B (en) 2013-02-22 2016-06-30 Upm Kymmene Corp Nanofibril polysaccharide for use in the control and prevention of constriction and scarring
CN103520739B (zh) 2013-10-22 2015-01-28 东北林业大学 一种纤维素纳米纤丝和吲哚美辛自组装复合体系的制备方法
FI126854B (en) * 2013-12-30 2017-06-30 Upm Kymmene Corp The membrane, its use and the method for making the membrane
FI3922279T3 (fi) 2016-08-30 2025-02-04 Dana Farber Cancer Inst Inc Lääkkeenantokoostumuksia ja niiden käyttötapoja
EP3791858A1 (en) 2019-09-13 2021-03-17 UPM-Kymmene Corporation Injectable pharmaceutical formulation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014533296A (ja) 2011-11-15 2014-12-11 ユー ピー エム キュンメネ コーポレーションＵｐｍ−Ｋｙｍｍｅｎｅｃｏｒｐｏｒａｔｉｏｎ 生物活性剤の持続性送達のためのドラッグデリバリーシステム
US20150335753A1 (en) 2012-12-19 2015-11-26 Kashiv Pharma, Llc Supersaturated stabilized nanoparticles for poorly soluble drugs
JP2017155195A (ja) 2016-03-04 2017-09-07 第一工業製薬株式会社 パラミロン水性分散液及び細胞増殖促進剤

Also Published As

Publication number Publication date
CN112494430A (zh) 2021-03-16
EP3791864A1 (en) 2021-03-17
JP2021046392A (ja) 2021-03-25
CN112494430B (zh) 2023-06-02
US20210077403A1 (en) 2021-03-18
KR20210032280A (ko) 2021-03-24
US11723867B2 (en) 2023-08-15

Similar Documents

Publication Publication Date Title
JP7640065B2 (ja) 医薬組成物を調製する方法及び医薬組成物
Abo-Elseoud et al. Chitosan nanoparticles/cellulose nanocrystals nanocomposites as a carrier system for the controlled release of repaglinide
Yang et al. Carboxymethyl β-cyclodextrin grafted carboxymethyl chitosan hydrogel-based microparticles for oral insulin delivery
Lin et al. Supramolecular hydrogels from in situ host–guest inclusion between chemically modified cellulose nanocrystals and cyclodextrin
JP7069484B2 (ja) 注射可能な医薬製剤
CN110087633B (zh) 干燥包含纳米原纤纤维素的水凝胶的方法以及包含纳米原纤纤维素的干燥的水凝胶
Najafi et al. Preparation and characterization of acetylated starch nanoparticles as drug carrier: Ciprofloxacin as a model
Ning et al. Synthesis and biological evaluation of surface-modified nanocellulose hydrogel loaded with paclitaxel
Rostamabadi et al. Cellulose nanofibers, nanocrystals, and bacterial nanocellulose: Fabrication, characterization, and their most recent applications
Padil et al. Dodecenylsuccinic anhydride derivatives of gum karaya (Sterculia urens): Preparation, characterization, and their antibacterial properties
Wang et al. Kinetics and antioxidant capacity of proanthocyanidins encapsulated in zein electrospun fibers by cyclic voltammetry
Rashki et al. Cellulose-based nanofibril composite materials as a new approach to fight bacterial infections
Li et al. Melatonin loaded with bacterial cellulose nanofiber by Pickering-emulsion solvent evaporation for enhanced dissolution and bioavailability
Ciftci et al. Fabrication of polycaprolactone-chitosan/curcumin polymer composite fibers and evaluation of their in vitro release kinetic behavior and antibacterial-antifungal activity
Abuelella et al. Polysaccharide based biomaterials for dermal applications
Zambuzi et al. Pectin/poly (ethylene oxide)/zein/hydroxypropyl methylcellulose acetate succinate-based fibers with nanocellulose for controlled hydroxychloroquine release
Sapa et al. Cellulose and cellulose derivatives in drug delivery
Nasirinezhad et al. A Comprehensive Review of Sources, Structure, Characteristics, Extraction, and Applications of Pectin in Drug Delivery
Kashid et al. Biopolymer-based nanomaterials: synthesis, characterization, and applications
Dotto et al. Frontiers in biomaterials
Yusefi et al. 5-Fluorouracil Encapsulated Chitosan-Cellulose Fiber Bionanocomposites: Synthesis, Characterization and In Vitro Analysis towards Colorectal Cancer Cells. Nanomaterials 2021, 11, 1691
Umar et al. Porous and highly responsive polymeric fabricated nanometrices for solubility enhancement of acyclovir; characterization and toxicological evaluation
Baek Modified Cellulose Nanocrystals (CNC) for Functional Foods
Dudhani et al. Mitigating Sublime Nature of Camphor via Pickering Emulsion Method for Sustained Antibacterial Efficacy
Yusefi et al. Preparation and characterization of cross-linked chitosan/cellulose bionanohybrids

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230802

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230802

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240820

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250121

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250213

R150 Certificate of patent or registration of utility model

Ref document number: 7640065

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150